No connection

Search Results

BGB vs HQL

BGB
Blackstone Strategic Credit 2027 Term Fund
BEARISH
Price
$11.90
Market Cap
$531.5M
Sector
Financial Services
AI Confidence
78%
HQL
Abrdn Life Sciences Investors
BULLISH
Price
$17.56
Market Cap
$534.0M
Sector
Financial Services
AI Confidence
75%

Valuation

P/E Ratio
BGB
11.55
HQL
6.29
Forward P/E
BGB
--
HQL
--
P/B Ratio
BGB
--
HQL
1.01
P/S Ratio
BGB
--
HQL
275.47
EV/EBITDA
BGB
--
HQL
--

Profitability

Gross Margin
BGB
0.0%
HQL
100.0%
Operating Margin
BGB
0.0%
HQL
-346.83%
Profit Margin
BGB
0.0%
HQL
4415.74%
ROE
BGB
--
HQL
17.59%
ROA
BGB
--
HQL
-0.43%

Growth

Revenue Growth
BGB
--
HQL
-69.9%
Earnings Growth
BGB
--
HQL
259.4%

Financial Health

Debt/Equity
BGB
--
HQL
--
Current Ratio
BGB
--
HQL
0.73
Quick Ratio
BGB
--
HQL
0.71

Dividends

Dividend Yield
BGB
8.39%
HQL
12.76%
Payout Ratio
BGB
107.18%
HQL
65.23%

AI Verdict

BGB BEARISH

The Advanced Deterministic Scorecard reveals critical weaknesses in BGB's financial health, with a Piotroski F-Score of just 1/9 indicating severe operational and balance sheet distress. Despite a current price of $11.90 and a seemingly attractive P/E of 11.55, the complete absence of profitability across all margin metrics and a dangerously high payout ratio of 107.18% undermine sustainability. The lack of Altman Z-Score data prevents precise bankruptcy risk modeling, but the weak F-Score and negative cash flow indicators suggest elevated risk. While the 8.39% dividend yield appears appealing, it is not supported by earnings or cash flow, raising concerns about future cuts.

Strengths
High dividend yield of 8.39% offers income appeal in a low-yield environment
Trading at a discount to sector average P/E (11.55 vs 31.00), suggesting potential valuation appeal
Positive long-term price performance: +38.8% over 5 years and +43.3% over 3 years
Risks
Piotroski F-Score of 1/9 indicates severe financial distress and poor fundamental health
Payout ratio of 107.18% implies dividends are not covered by earnings, threatening sustainability
Zero profitability across all margin metrics (Profit, Operating, and Gross Margins all at 0.00%)
HQL BULLISH

HQL presents as a deep-value opportunity, anchored by a stable Piotroski F-Score of 6/9 and a significant valuation gap, with a current price of $17.56 trading well below its Graham Number ($33.01) and Intrinsic Value ($82.31). While the company exhibits severe operational anomalies—specifically a -69.90% revenue collapse and a deeply negative operating margin—the massive earnings growth and low P/E ratio (6.29) suggest the entity is benefiting from significant investment gains rather than core fee income. The high dividend yield of 12.76% is supported by a sustainable payout ratio, though the bearish technical trend (10/100) suggests a period of consolidation or price correction is underway.

Strengths
Extreme undervaluation relative to Graham Number ($33.01) and Intrinsic Value ($82.31)
Very low P/E ratio (6.29) compared to the sector average of 36.83
Strong dividend yield of 12.76% with a manageable payout ratio (65.23%)
Risks
Severe revenue decline (-69.90% YoY) indicating a collapse in core business growth
Poor operational efficiency with an operating margin of -346.83%
Liquidity risk evidenced by a current ratio of 0.73 (below 1.0)

Compare Another Pair

BGB vs HQL: Head-to-Head Comparison

This page compares Blackstone Strategic Credit 2027 Term Fund (BGB) and Abrdn Life Sciences Investors (HQL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile